Model-informed early clinical development of BI-1808, a novel monoclonal antibody to tumor necrosis factor receptor 2

Oncology

MIDD

Trial design and analysis

PAGE 32 (2024) Abstr 10786

Mc Laughlin AM, Janssen JM, Borggren M, Teige I, Wallin J

External authors

Borggren M,

Teige I,

Wallin J

Pharmetheus collaborators